<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/63E84433-DCF0-43B3-9DC6-108921625A22"><gtr:id>63E84433-DCF0-43B3-9DC6-108921625A22</gtr:id><gtr:name>Van Andel Institute</gtr:name><gtr:address><gtr:line1>Van Andel Institute</gtr:line1><gtr:line2>333 Bostwick Avenue NE</gtr:line2><gtr:postCode>MI 49503</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/63E84433-DCF0-43B3-9DC6-108921625A22"><gtr:id>63E84433-DCF0-43B3-9DC6-108921625A22</gtr:id><gtr:name>Van Andel Institute</gtr:name><gtr:address><gtr:line1>Van Andel Institute</gtr:line1><gtr:line2>333 Bostwick Avenue NE</gtr:line2><gtr:postCode>MI 49503</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2BE9A55F-1542-427E-877B-EF4684BF041C"><gtr:id>2BE9A55F-1542-427E-877B-EF4684BF041C</gtr:id><gtr:firstName>Ermanno</gtr:firstName><gtr:surname>Gherardi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800025"><gtr:id>6A808DFF-717F-4351-82C9-2D73107BAF33</gtr:id><gtr:title>Structure/function of HGF/SF and MET</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800025</gtr:grantReference><gtr:abstractText>The most important cause of death in patients with cancer is the migration of cancer cells away from the primary tumour and the emergence of secondary tumours at distance sites in the body, a process called metastasis. At present there are very few effective treatments for metastatic cancer but this situation is bound to change in the coming years because the key signals that cause cancer cells to migrate are now known and the in depth study of these molecules will lead to new therapies. In this project we aim to determine the structure of HGF/SF and MET, two proteins critical for initiating the migration of cancer cells. We have carried out the background work necessary for this work and are confident that we can achieve the objective proposed and use this knowledge in order to contribute to the development of new treatments for metastatic cancer.</gtr:abstractText><gtr:technicalSummary>This proposal is for structural studies of the growth and motility factor HGF/SF and its receptor MET as well as for development of low molecular weight MET antagonists. HGF/SF and MET are essential for embryogenesis and tissue regeneration and play a critical role in cancer invasion and metastasis. Hence, in addition to their key physiological roles, these molecules have emerged in recent years as major targets for cancer therapy. In order to tackle the structure of HGF/SF-MET complexes we have first defined the domain structure of extracellular MET by deletion mutagenesis, ligand binding experiments and homology modelling. Next, we have used cryo-electron microscopy and small angle X-ray scattering to produce low-resolution structures of the inactive (single-chain) and active (two-chain) forms of HGF/SF in complex with the MET ectodomain. These experiments have enabled us: (i) to identify the MET fragments most appropriate for crystallography and, (ii) obtain crystals of a ternary complex composed of two-chain HGF/SF, MET and a heparin fragment. We propose to extend the work on this complex in order to obtain a high-resolution structure of the two-chain-MET complex and generate, in parallel, crystals of the corresponding complex with single-chain HGF/SF. Comparison of the MET structures in complex with the inactive and active forms of the ligand will provide conclusive insights into the molecular mechanism of MET activation by HGF/SF. In a separate and complementary line of experiments, we will use NK1 and the SP fragments of HGF/SF, namely the domains comprising the high and low affinity binding sites for MET, in order to develop low molecular weight inhibitors. The studies proposed will define the structural basis for MET activation by HGF/SF and generate lead compounds for the therapy of metastatic cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2011-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>466173</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Van andel Research Institute (VARI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Structural Sciences</gtr:department><gtr:description>Engineering HGF/SF fragments as receptor antagonists</gtr:description><gtr:id>C521A27F-BC06-42A8-A761-E46085FFB8D2</gtr:id><gtr:impact>Several publications.</gtr:impact><gtr:partnerContribution>Dr Eric Xu and his collaborators have been addressing the structure and function of two fragments of HGF/SF (NK1 and NK2) in order to understand the basis for receptor activation or antagonism. They have expressed these proteins and several mutants of them in bacteria and determined crystal structures of both NK1 and a mutant variant of NK2. These studies established a requirement for dimerisation for agonistic activity and offered a way to engineer both NK1 and NK2 as MET antagonists.</gtr:partnerContribution><gtr:piContribution>Our laboratory has been interested in the structure of HGF/SF and several truncated variants of HGF/SF, such as NK1 and NK2, for several years. Our work and initial independent studies by Dr Xu and his colleagues at the Van Andel Institute appeared to be complementary and formed the basis for a collaborative programme of work in which we suceeded in developing protein antagonists of the MET receptor using the natural ligand HGF/SF as a starting point.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz Centre for Infection Research (HZI)</gtr:department><gtr:description>Structure of InlB-MET complexes</gtr:description><gtr:id>C63A3D92-7701-4D3F-804F-364156103EF5</gtr:id><gtr:impact>Several publications.</gtr:impact><gtr:partnerContribution>Dr Dirk Heinz's laboratory has worked for a number of years on the structure and functional of proteins of L monocytogenes involved in pathogenecity. One of these proteins, known as InlB, is a ligand for the MET receptor, a protein studied in our laboratory. Dr Heinz's and his colleagues produced InlB variants andd crystallised the complex between InlB321 and a fragment of the MET ectodomain.</gtr:partnerContribution><gtr:piContribution>Our laboratory has contributed MET constructs and MET-expressing cell lines to the project. It also carried physico-chemical analysis of ligand-receptor complexes by analytical ultracentrifugation and biological studies aimed at defining the activity of the InlB ligands and validating the conclusions of the crystal structure.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>274533</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3B4673B1-EECE-450C-9003-37253EC0FE66</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>759000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Seventh Framework Programme</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:id>3D629075-E717-4AC6-B249-7D840C87AEEC</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method for producing soluble fragments of the ectodomain of the MET receptor and the use of such fragments in order to screen for agents that may block the binding of HGF/SF to MET.</gtr:description><gtr:id>0C7BE760-AEEA-4C78-99DD-3455EB285E49</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2007037209</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Soluble fragments of the MET receptor</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Linker mutants of the NK1 fragment of HGF/SF with receptor antagonistic activity.</gtr:description><gtr:id>EF79FD65-179C-4F05-8829-AC42A1DA14A1</gtr:id><gtr:impact>These protein variants have significant receptor antagonistic activity and are being explored for their activity as inhibitors of the MET receptor.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Growth factor variants</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB33A53F-7C92-4268-9DD4-04A246F63440"><gtr:id>BB33A53F-7C92-4268-9DD4-04A246F63440</gtr:id><gtr:title>Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b04458a97b7eafbb460142cf6ae2dc0"><gtr:id>7b04458a97b7eafbb460142cf6ae2dc0</gtr:id><gtr:otherNames>Sinha Roy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42E65FE7-954A-4D2D-A0CF-34DBC5E56FA0"><gtr:id>42E65FE7-954A-4D2D-A0CF-34DBC5E56FA0</gtr:id><gtr:title>Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4da106ff90ea5e7644df5f6705e72dd7"><gtr:id>4da106ff90ea5e7644df5f6705e72dd7</gtr:id><gtr:otherNames>Youles M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B733586-7C29-4025-8B93-D79D7397A6F7"><gtr:id>3B733586-7C29-4025-8B93-D79D7397A6F7</gtr:id><gtr:title>Structural basis for agonism and antagonism of hepatocyte growth factor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb3a4c4aac6c39218e08d4481cd8d8dc"><gtr:id>bb3a4c4aac6c39218e08d4481cd8d8dc</gtr:id><gtr:otherNames>Tolbert WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3182D9A1-EF43-466D-9DD6-EA88440F9A1E"><gtr:id>3182D9A1-EF43-466D-9DD6-EA88440F9A1E</gtr:id><gtr:title>Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b424508a3ea37dc0eb9aa9a82054bc1c"><gtr:id>b424508a3ea37dc0eb9aa9a82054bc1c</gtr:id><gtr:otherNames>Catlow KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/72F5D4C1-7533-4123-87B1-D03A10C3B2AD"><gtr:id>72F5D4C1-7533-4123-87B1-D03A10C3B2AD</gtr:id><gtr:title>X-ray and neutron small-angle scattering analysis of the complex formed by the Met receptor and the Listeria monocytogenes invasion protein InlB.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/968f5a51fae20554b7dbe6e06097a10c"><gtr:id>968f5a51fae20554b7dbe6e06097a10c</gtr:id><gtr:otherNames>Niemann HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52523F48-A320-4FBD-B830-56542BBBC8D4"><gtr:id>52523F48-A320-4FBD-B830-56542BBBC8D4</gtr:id><gtr:title>A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.</gtr:title><gtr:parentPublicationTitle>Applied immunohistochemistry &amp; molecular morphology : AIMM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fc3cc8b4072d49cf7d899506e27e0e8c"><gtr:id>fc3cc8b4072d49cf7d899506e27e0e8c</gtr:id><gtr:otherNames>Knudsen BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1533-4058</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/783024E2-971C-44F3-8458-8EDBF2237547"><gtr:id>783024E2-971C-44F3-8458-8EDBF2237547</gtr:id><gtr:title>Engineered variants of InlB with an additional leucine-rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complex.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/968f5a51fae20554b7dbe6e06097a10c"><gtr:id>968f5a51fae20554b7dbe6e06097a10c</gtr:id><gtr:otherNames>Niemann HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3E77693-1526-4EEC-8ED5-001D8EB0FD56"><gtr:id>C3E77693-1526-4EEC-8ED5-001D8EB0FD56</gtr:id><gtr:title>Ligand-mediated dimerization of the Met receptor tyrosine kinase by the bacterial invasion protein InlB.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eaf2441769bedd6621f96b3d1c3e62cb"><gtr:id>eaf2441769bedd6621f96b3d1c3e62cb</gtr:id><gtr:otherNames>Ferraris DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/578D75E5-798B-4BA4-BEF1-F9367F3D837A"><gtr:id>578D75E5-798B-4BA4-BEF1-F9367F3D837A</gtr:id><gtr:title>Targeting MET in cancer: rationale and progress.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73099a715c34b49f3fb33f13d128e7cc"><gtr:id>73099a715c34b49f3fb33f13d128e7cc</gtr:id><gtr:otherNames>Gherardi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CFBBFC28-59B8-4952-B44A-2C79A1DD5767"><gtr:id>CFBBFC28-59B8-4952-B44A-2C79A1DD5767</gtr:id><gtr:title>Glycoprotein production for structure analysis with stable, glycosylation mutant CHO cell lines established by fluorescence-activated cell sorting.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6e664734022dc98c793c5ff0b77dcdc1"><gtr:id>6e664734022dc98c793c5ff0b77dcdc1</gtr:id><gtr:otherNames>Wilke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA964AE9-990B-4410-B0AD-0278EEEB2629"><gtr:id>AA964AE9-990B-4410-B0AD-0278EEEB2629</gtr:id><gtr:title>Crystal structure of an engineered YopM-InlB hybrid protein.</gtr:title><gtr:parentPublicationTitle>BMC structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1c9c527c051e583b902f156c318dfde"><gtr:id>b1c9c527c051e583b902f156c318dfde</gtr:id><gtr:otherNames>Breitsprecher D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-6807</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800025</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>